

# Nathalie Le Bastard

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6214818/publications.pdf>

Version: 2024-02-01

13  
papers

1,028  
citations

759233

12  
h-index

1125743

13  
g-index

13  
all docs

13  
docs citations

13  
times ranked

1693  
citing authors

#	ARTICLE	IF	CITATIONS
1	Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. <i>Biomarkers in Medicine</i> , 2012, 6, 419-430.	1.4	280
2	Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative. <i>Alzheimer's and Dementia</i> , 2012, 8, 65-73.	0.8	271
3	Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 1815-1824.	3.7	104
4	Increased CSF $\alpha$ -synuclein levels in Alzheimer's disease: Correlation with tau levels. <i>Alzheimer's and Dementia</i> , 2014, 10, S290-8.	0.8	69
5	Added diagnostic value of CSF biomarkers in differential dementia diagnosis. <i>Neurobiology of Aging</i> , 2010, 31, 1867-1876.	3.1	63
6	No correlation between time-linked plasma and CSF $A\beta$ levels. <i>Neurochemistry International</i> , 2009, 55, 820-825.	3.8	53
7	Importance and Impact of Preanalytical Variables on Alzheimer Disease Biomarker Concentrations in Cerebrospinal Fluid. <i>Clinical Chemistry</i> , 2015, 61, 734-743.	3.2	53
8	Comparison of Two Analytical Platforms for the Clinical Qualification of Alzheimer's Disease Biomarkers in Pathologically-Confirmed Dementia. <i>Journal of Alzheimer's Disease</i> , 2012, 33, 117-131.	2.6	40
9	Comparing CSF amyloid $\beta$ biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12182.	2.4	26
10	Plasma Amyloid- $\beta$ Forms in Alzheimer's Disease and Non-Alzheimer's Disease Patients. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 291-301.	2.6	25
11	Impact of CSF storage volume on the analysis of Alzheimer's disease biomarkers on an automated platform. <i>Clinica Chimica Acta</i> , 2019, 490, 98-101.	1.1	17
12	Overdiagnosing Vascular Dementia using Structural Brain Imaging for Dementia Work-Up. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 1039-1043.	2.6	15
13	Added Diagnostic Value of Cerebrospinal Fluid Biomarkers for Differential Dementia Diagnosis in an Autopsy-Confirmed Cohort. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 373-381.	2.6	12